Hackensack Meridian Health Joseph M. Sanzari Children’s Hospital Researchers at the Forefront of Decreasing Therapy for Children and Young Adults with a Type of Hodgkin Lymphoma

Select Patients with LPHL May Be Spared Chemotherapy

Burton Appel, M.D., a Joseph M. Sanzari Children’s Hospital pediatric oncologist, led the only prospective study for pediatric patients with lymphocyte predominant Hodgkin lymphoma (LPHL) which demonstrated that in some cases, 75% of pediatric patients with LPHL may be spared chemotherapy after surgical resection alone.

Pediatric LPHL has excellent cure rates with chemotherapy that is less intensive than standard regimens; 90% of patients can avoid radiation therapy.

Dr. Appel is now planning a follow up study for patients with LPHL. In addition, the hospital is one of 56 sites in the U.S. (and one of only two in New Jersey) to offer an international study (AHOD1721) for relapsed Hodgkin lymphoma, designed to improve cure rates while limiting long-term side effects. The hospital recently enrolled the 18th patient on this study worldwide for patients who receive the least amount of therapy.

Learn more about advances in pediatric oncology happening at Joseph M. Sanzari Children’s Hospital and K. Hovnanian Children's Hospital by visiting: